Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Orexigen Therapeutic (OREX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,422
  • Shares Outstanding, K 16,600
  • Annual Sales, $ 33,710 K
  • Annual Income, $ -24,520 K
  • 36-Month Beta 2.31
  • Price/Sales 0.23
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.14 +1.75%
on 12/26/17
1.33 -12.78%
on 12/27/17
-0.04 (-3.33%)
since 12/18/17
3-Month
1.14 +1.75%
on 12/26/17
1.91 -39.27%
on 11/13/17
-0.71 (-37.97%)
since 10/18/17
52-Week
1.14 +1.75%
on 12/26/17
5.70 -79.65%
on 02/10/17
-2.32 (-66.67%)
since 01/18/17

Most Recent Stories

More News
Super Savings: Inside Rx Expands Its Prescription Savings Program, Offers Discounts on 100 Brand Name Medications

Inside Rx announced today the addition of 30 new brand-name prescription medications to its featured medications list, bringing the total number of discounted brand medications available through the ground-breaking...

OREX : 1.16 (-0.85%)
ESRX : 80.00 (-0.97%)
Orexigen Struggles as Contrave Commercialization Costs Rise

Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

OREX : 1.16 (-0.85%)
NVO : 56.51 (+0.18%)
VVUS : 0.47 (unch)
ARNA : 34.12 (-0.70%)
Implied Volatility Surging for Orexigen (OREX) Stock Options

Investors in Orexigen Therapeutics (OREX) need to pay close attention to the stock based on moves in the options market lately.

OREX : 1.16 (-0.85%)
Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.

OREX : 1.16 (-0.85%)
SCMP : 17.95 (-0.28%)
TEVA : 20.71 (-3.58%)
MKGAF : 110.8900 (-1.17%)
Orexigen Therapeutics Announces Third Quarter 2017 Financial Results

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the third quarter ended September 30, 2017.

OREX : 1.16 (-0.85%)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Merck KGaA, Darmstadt, Germany have executed a distributorship agreement...

OREX : 1.16 (-0.85%)
MKKGY : 22.1750 (-1.36%)
Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13, 2017

Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the third quarter of 2017 on Monday, November 13th after the market closes. Following the announcement, Orexigen...

OREX : 1.16 (-0.85%)
Today's Research Reports on Trending Tickers: Corcept Therapeutics and Orexigen Therapeutics

NEW YORK, NY / ACCESSWIRE / October 16, 2017 / U.S. markets rose Friday to close the week in the green as investors appear to be expecting a strong earnings season. The Dow Jones Industrial Average gained...

CORT : 23.58 (+6.26%)
OREX : 1.16 (-0.85%)
Orexigen Announces Favorable Decision from U.S. District Court in Patent Litigation, Confirming Exclusivity for Contrave Through 2030

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that the United States District Court for the District of Delaware issued a ruling in favor of Orexigen in the paragraph IV litigation against...

OREX : 1.16 (-0.85%)
Orexigen's (OREX) Contrave Sales Improving on Promotions

Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

OREX : 1.16 (-0.85%)
NVO : 56.51 (+0.18%)
VVUS : 0.47 (unch)
ARNA : 34.12 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III...

See More

Key Turning Points

2nd Resistance Point 1.22
1st Resistance Point 1.19
Last Price 1.16
1st Support Level 1.14
2nd Support Level 1.12

See More

52-Week High 5.70
Fibonacci 61.8% 3.96
Fibonacci 50% 3.42
Fibonacci 38.2% 2.88
Last Price 1.16
52-Week Low 1.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.